
SINTX Technologies Files Multiple New U.S. and International Patent Applications
May 7, 2021
This week SINTX Technoloiges announced multiple U.S. and international patent applications for development of new technologies utilizing the company’s silicon nitride.
“The innovative application of SINTX’s silicon nitride promises new tools to improve our public health response to COVID-19 and other viruses,” said Kelvyn Cullimore, president and CEO of BioUtah.
SINTX has found that its silicon nitrate material inactivates COVID-19, H1N1 and the common flu within seconds and continues to develop applications to fight against viral diseases, including masks, medical gowns, IT devices, air filters, and much more.
The following expand on several existing antipathogenic and coating-technology patent applications:
- Systems and Methods for Rapid Inactivation of SARS-CoV-2 by Silicon Nitride, Copper and Aluminum Nitride
- Antipathogenic Composites and Devices and Methods of Use Thereof
- Antipathogenic Face Mask
- Systems and Methods for Physical Vapor Deposition of Silicon Nitride Coatings Having Antimicrobial and Osteogenic Enhancements
- Methods of Silicon Nitride Laser Cladding
- Methods for Laser Coating of Silicon Nitride on a Metal Substrate
The patent applications largely relate to the development of antipathogenic and/or osteogenic composite systems, methods, devices, and surface coatings. The technologies can be applied in antipathogenic devices such as face masks and filters, or in medical devices such as orthopedic, wound care dressings, and dental implants.
The patent applications are an important milestone in SINTX’s commitment to leverage the inherent antipathogenic and osteogenic properties of silicon nitride in powders and coatings to address viral diseases such as COVID-19 and to improve outcomes in medical device implantations.
Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- Utah Business, Government Leaders Deepen Connections in Ireland
- Co-Diagnostics’ Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara’s SARAGENE® Test














